Richard Colvin compensation by year
bluebird bio Summary Compensation Table · all 2 fiscal years held| Component | FY2022 | FY2023 |
|---|---|---|
| Salary | $467,639 | $489,808 |
| Bonus | $0 | $0 |
| Stock awards | $294,240 | $281,050 |
| Option awards | $374,297 | $371,800 |
| Non-equity incentive | $216,000 | $187,425 |
| Pension and deferred compensation | $0 | $0 |
| All other | $12,600 | $14,170 |
| Total | $1,364,776 | $1,344,253 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: bluebird bio, Inc. DEF 14A filed September 26, 2024, accession 0001293971-24-000049, and prior-year filings. Open the filing on EDGAR.
How this page was built: the bluebird bio, Inc. filed document, accession 0001293971-24-000049. Every figure is read from that document and cited to the page and table it appears in. Filed September 26, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 55,000 | $75,900 | — |
| RSU | 22,500 | $31,050 | — |
| RSU | 10,039 | $13,854 | — |
| RSU | 9,975 | $13,766 | — |
| RSU | 2,009 | $2,772 | — |
| RSU | 555 | $766 | — |
| Option | 43,750 | — | $6.35 |
| Option | 2,195 | — | $14.17 |
| Option | 124 | — | $36.78 |
| Option | 110,000 | — | $5.11 |
| Option | 12,580 | — | $14.99 |
| Option | 14,300 | — | $7.80 |
Per the Outstanding Equity Awards at Fiscal Year-End table in bluebird bio, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
7 Form 4 lines since the FY2023 proxy (filed September 26, 2024)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-06-02 | Disposition to the issuer | — | 4,166 | — | 0 |
| 2025-06-02 | Grant or award | — | 2,500 | — | 2,500 |
| 2025-06-02 | Disposition to the issuer | — | 2,500 | — | 0 |
| 2025-05-30 | U | — | 3,552 | — | 4,166 |
| 2025-03-03 | Sale | 10b5-1 | 584 | $3.92 | 7,610 |
| 2025-02-03 | Sale | 10b5-1 | 64 | $7.39 | 8,194 |
| 2025-01-06 | Sale | 10b5-1 | 19 | $9.24 | 8,257 |
The 7 most recent of 7 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
bluebird bio’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Andrew Obenshain | Chief Executive Officer | $3,049,181 |
| Richard Colvin · this page | Chief Medical Officer | $1,344,253 |
| Thomas Klima | Chief Commercial and Operating Officer | $1,329,535 |
The full bluebird bio compensation record
free company briefThis page is one person within bluebird bio's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are bluebird bio's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.